RT Journal Article
T1 High density lipoprotein subfractions and extent of coronary atherosclerotic lesions: From the cordioprev study.
A1 de la Cruz-Ares, Silvia
A1 Leon-Acuña, Ana
A1 Yubero-Serrano, Elena M
A1 Torres-Peña, Jose D
A1 Arenas-de Larriva, Antonio P
A1 Cardelo, Magdalena P
A1 Rangel-Zuñiga, Oriol A
A1 Luque, Raul M
A1 Alcala-Diaz, Juan F
A1 Ordovas, Jose M
A1 Perez-Martinez, Pablo
A1 Lopez-Miranda, Jose
A1 Delgado-Lista, Javier
K1 Angiography severity
K1 Atherosclerosis
K1 Cardiovascular risk factors
K1 HDL particles
K1 Lipoprotein subfractions
AB The extent of atherosclerotic coronary heart disease (CHD) is associated with its prognosis, thus discovering potential biomarkers related to worse outcomes could prove valuable. The present work aims to investigate whether lipoprotein subfractions are associated with angiographic CHD severity. Patients from the CORDIOPREV study exhibiting coronary lesions in angiography were classified into two groups (single-vessel coronary disease (SVD) or multivessel coronary disease (MVD)). High-throughput nuclear magnetic resonance (NMR) spectroscopy determined lipoprotein subfractions concentration and composition. SVD patients showed a higher concentration of medium and small HDL particles compared with MVD patients. For medium HDL, total lipids, phospholipids, total cholesterol, cholesteryl esters and free cholesterol reflected HDL particle concentration, whereas, for small HDL, total lipids, phospholipids, and free cholesterol mirrored lipoprotein particle concentration. Among traditional cardiovascular risk factors, age, hypertension and T2D were independently associated with angiography severity. In multivariate logistic regression models, medium and small HDL particles remained inversely associated with angiography severity (OR 0.77 (95% CI: 0.64-0.91); OR 0.78 (95% CI: 0.67-0.91), respectively) after adjusting with covariates. In CHD patients mostly on statin treatment, angiography severity is inversely related to small and medium HDL subclasses concentration measured by NMR. These particles are also independent predictors of the presence of MVD, and its use increased the prediction of this entity over traditional risk factors.
PB Elsevier
YR 2022
FD 2022-06-03
LK http://hdl.handle.net/10668/22074
UL http://hdl.handle.net/10668/22074
LA en
NO de la Cruz-Ares S, Leon-Acuña A, Yubero-Serrano EM, Torres-Peña JD, Arenas-de Larriva AP, Cardelo MP, et al. High density lipoprotein subfractions and extent of coronary atherosclerotic lesions: From the cordioprev study. Clin Chim Acta. 2022 Aug 1;533:89-95
NO We would like to thank the Escuela Andaluza de Salud Publica (EASP), Granada (Spain), for carrying out the randomization process in this study. The CIBER Physiopathology of Obesity and Nutrition (CIBEROBN) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain.  Funding sources The CORDIOPREV study was supported by the Fundacion Patri monio Comunal Olivarero https://www.patrimoniolivarero.com/fundacion, Cordioprev-CEAS, 1/2016 to JLM). This study also received  research grants from Consejeria de Economia, Innovacion, Ciencia y Empleo (https://www.juntadeandalucia.es, CVI-7450 and P20-00256 to  JLM) and Ministerio de Ciencia e Innovacion (http://www. ciencia.gob. es, AGL2012-39615, AGL2015-67896-P and PID2019-104362RB-I00 to JLM), integrated into the framework of the National Plan for Scientific Research, Technological Development and Innovation 2013-2016, co-financed by the Instituto de Salud Carlos III (ISCIII) of Spain and also by the Directorate General for Assessment and Promotion of Research and the EU’s European Regional Development Fund (FEDER). ALA is supported by an ISCIII research contract (Programa Juan Rodes JR19/ 00034). EMYS is the recipient of the Nicolas Monardes Programme from the “Servicio Andaluz de Salud, Junta de Andalucia,” Spain (C1-0005- 2019). OARZ is supported by an ISCIII research contract (Programa Miguel-Servet CP19/00142). APAL is supported by an ISCIII research contract (Programa Rio Hortega, CM20/00242). MPC is supported by an ISCIII PFIS fellowship (FI17/00081).
DS RISalud
RD Apr 8, 2025